Next Phase Newsletter

A San Francisco based venture platform founded in 2016 focuses on early stage healthcare companies. The firm currently has 34 companies in their portfolio with 4 exits. The firm invests in all 4 life science sectors and the typical check size ranges from $100K – 500K and typically helps fill out existing rounds once there is a lead investor in-place. The firm generally seeks to make investments into emerging life science companies in Pre-Seed, Seed and Series A stages. The firm is US focused in terms of geographic preference, but will occasionally look outside of the US.

The firm invests across all life science verticals and is open to all 4 sectors. The firm looks for novel technologies in biotech, medtech, digital health therapeutics, and diagnostics. In terms of biotech companies, the firm focuses on biotechnology platforms rather than single asset biotech companies. The firm is agnostic to both subsector and indication and is open to both pre-clinical therapeutic companies as well as all three stages of medical devices.

The firm is open to all types of management teams, with a goal to democratize who gets funding in the life science space. The firm is looking for diversity in the management team to combine ideas and skill set. The firm prefers to co-invest rather than lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An investor group founded in 2010 and based in California is an investing ecosystem that includes Accredited Angel Investors, Healthcare Systems, and Corporate Venture Investors. The firm focuses on healthcare IT, services and digital health from providers to consumers that changes the landscape of healthcare delivery. The firm prides itself in having built an ecosystem of qualified venture investors, corporate leaders and healthcare providers that open doors to strategic expertise and collaboration in the healthcare IT space. As an Angel-stage investor, the firm’s typical investment size can range, and can go from $100,000 to several million dollars. The firm also co-invests, and has made 24 series A/B investments so far, and is expecting 4-5 new investments and 4-5 repeat investments within the next year. The firm is open to companies throughout the USA, and has historically reviewed companies in Canada, though based on experience, prefer those that can manage the logistics of geographical distance.

The firm focuses on healthcare IT, service, and digital health from providers to consumers that have a working prototype with an early pilot traction. The firm seeks products that serve hospitals at all parts of the continuum care spectrum, reaching to chronic care services that are past discharge and into long-term outpatient care. The firm also invests in devices that go to the consumer, as well as software-enabled technologies, such as connection technologies (i.e. Bluetooth, cell phone, etc.). The firm prefers no FDA regulated devices, and looks at pre-revenue technology with a foreseen horizon in terms of potential. The firm is also open to biotools and lab equipment, as they have historically invested in software and service models in the genomics area and technologies that organize clinical trials.

While a management team must be in place, the firm has an experienced team of members with the ability to mentor and fill management teams with expertise. The firm typically takes a board seat after leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A private investment firm based in China is focused on medical device technologies. The firm is formed by pharmaceutical and medical device industry veterans and high-net-worth individuals, and typical investment size ranges from US$1-5 million. The firm is open to leading or following in a financing round. Since 2016, the firm has begun broadening its geographic exposure and is currently seeking seed to early-stage opportunities from the US, Canada, Israel, and China.

The firm is interested in unique, disruptive medical device technologies with a focus on the following target markets: ophthalmic diagnostic or therapeutic device; visual optics technology; home use and personal care device; in-vitro diagnostics (IVD); and surgical equipment and consumables. The firm considers products that have at least completed prototype and obtained in-vivo proof-of-concept.

The firm is looking for competent management teams with strong sector expertise. The firm can request board representation after investment on a case-by-case basis. The firm does not focus only on products with a China angle, however it can aid in identifying strategic partners in the Chinese market.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An active early stage venture fund with offices in Western Europe is led by a team composed of experienced professionals in funding, entrepreneurship and therapeutic development. Currently, the firm’s investment focus is in cell and gene therapy and their manufacturing technologies.

The firm is especially interested in companies developing therapeutic approaches, such as state of the art cell therapies in regenerative and autoimmune fields that need local manufacturing. The firm is primarily interested in early stage, pre-clinical breakthrough technologies seeking seed investment.

The firm takes an active role with the companies in which they invest. The firm frequently leads rounds, and supports and mentors the early stage companies, often either taking a board seat themselves or finding an expert to serve on the board. Apart of building companies, Delin Ventures is also interested in the investment in the existing companies, syndicating with other investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.